Freddy Yip

Associate
Full contact info

Experience

Cooley Supports Jiangsu Hengrui in Two Global License Agreements

November 8, 2023

Cooley advised Jiangsu Hengrui Pharmaceuticals, a leading global pharmaceutical company headquartered in China with a focus on research, development, manufacturing and commercialization of innovative and high-quality healthcare products, on its strategic collaboration and exclusive worldwide (excluding mainland China) license agreement with Merck KGaA, Darmstadt, Germany and global license agreement (excluding the Greater China region and Korea) with Elevar Therapeutics.

Read more

Related contacts

Christina Zhang
Partner, Shanghai
Freddy Yip
Associate, Hong Kong
Alan W. Tamarelli
Partner, New York
Bin Wang
Special Counsel, Palo Alto
Bill Christiansen
Partner, Seattle
Dr. Xixi Sun
Associate, Boston
Amanda Pacheco
Associate, Palo Alto
Brendan Haberle
Associate, San Diego
Howard Morse
Partner, Washington DC

Related Practices & Industries

Immatics Announces Collaboration With Moderna

September 11, 2023

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Stephanie Parker Palmer
Special Counsel, Reston
J. Brian Stalter
Special Counsel, New York
Carly Robinson
Associate, Reston
David D. Suh
Associate
Freddy Yip
Associate, Hong Kong
Jacqueline Grise
Partner, Washington DC
Sharon Connaughton
Special Counsel, Washington DC
Rubin Waranch
Associate, Washington DC
Alexander Israel
Partner in Charge – Brussels, Brussels
Stella Sarma
Special Counsel, Brussels
Jan Lang
Associate, Brussels
Kimberly Nguyen
Special Counsel, Reston
Liza Hadley
Associate, Boston
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Rachel Thorn
Partner, New York
Matthew Pavao
Partner, Boston

Related Practices & Industries

Senti Biosciences Sells Certain Assets to Celadon Partners

August 14, 2023

Cooley advised Senti Biosciences, a biotechnology company, on its sale of certain assets – including its manufacturing facility and chemistry, manufacturing, and controls capabilities – to Celadon Partners.

Read more

Related contacts

Maureen Nagle
Special Counsel, Washington DC
Luke X. Blackett
Associate, San Francisco
Chrystal Cantrelle
Associate, Washington DC
Rena Kaminsky
Special Counsel, Palo Alto
Freddy Yip
Associate, Hong Kong
Peter Crain
Special Counsel, Reston
Alanna B Zuchelli
Associate, Reston
Ross Eberly
Partner, Los Angeles Santa Monica
Marya Postner
Partner, Palo Alto
Helen Luu
Associate, Palo Alto
Aric Wu
Partner, New York
Rachel Thorn
Partner, New York
Barbara Mirza
Partner, Los Angeles Santa Monica
Christopher Kimball
Partner, Washington DC
Dee Bansal
Partner, Washington DC
Natasha Leskovsek
Of Counsel, Washington DC
Stacey A. Bradford
Special Counsel, Washington DC
J. Brian Stalter
Special Counsel, New York
Annie Froehlich
Special Counsel, Washington DC
Amanda Pacheco
Associate, Palo Alto
Zack Gong
Associate, Shanghai
Nicholas Balenger
Associate, Reston
Rachel Boyce
Associate, San Francisco
Ajay Athavale
Associate, San Francisco
Sarah Oliai
Associate, Washington DC
Leina Verrier
Associate, Los Angeles Santa Monica
Patricia Myers
Paralegal Specialist, Colorado

Related Practices & Industries

Cholesgen Enters Discovery Collaboration, Licensing Option Agreement With AstraZeneca

June 16, 2023

Cooley advised Cholesgen, a biopharmaceutical company focusing on metabolic diseases, on its three-year research collaboration and licensing agreement with AstraZeneca.

Read more

Related contacts

Christina Zhang
Partner, Shanghai
Freddy Yip
Associate, Hong Kong
Kay Chandler
Partner, San Diego

Related Practices & Industries

Zai Lab Announces Strategic Partnership, Exclusive Worldwide License Agreement With MediLink Therapeutics

May 15, 2023

Cooley advised Zai Lab, a research-based commercial-stage biopharmaceutical company, on its strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics, as part of Zai Lab’s efforts to build its portfolio of potential first- and/or best-in-class antibody-drug conjugate (ADC) products.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Freddy Yip
Associate, Hong Kong
Jameson Davis
Associate, Palo Alto
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

View more